MedTrace Logo

JY509 Universal NK Cell Injection for the Treatment of Relapsed/Refractory Pediatric B-ALL

NCT07406178 · Status: NOT_YET_RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2026-02-12

No results posted yet for this study

Summary

This is a single-arm, open-label, dose-escalation and expansion, prospective clinical trial conducted in patients with relapsed or refractory pediatric B-cell acute lymphoblastic leukemia to evaluate the safety and efficacy of JY509 universal NK cell injection.

Conditions

  • Relapsed/Refractory Pediatric B-ALL

Interventions

BIOLOGICAL

JY509 universal NK cell injection

3+3 dose escalation trial and dose expansion trial

Sponsors & Collaborators

  • Institute of Hematology & Blood Diseases Hospital, China

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
3 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-20
Primary Completion
2029-01-01
Completion
2029-04-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07406178 on ClinicalTrials.gov